Agios Pharmaceuticals (AGIO) Accounts Payables (2012 - 2026)

Agios Pharmaceuticals' Accounts Payables history runs 15 years deep, the most recent figure standing at $13.7 million for Q1 2026.

• Quarterly Accounts Payables changed 0.15% year-over-year to $13.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.7 million (changed 0.15% YoY) and the FY2025 annual result came in at $18.4 million, up 10.29% from the prior year.
• Accounts Payables was $13.7 million for Q1 2026 at Agios Pharmaceuticals, down from $18.4 million in the prior quarter.
• Across five years, Accounts Payables topped out at $19.6 million in Q3 2025 and bottomed at $7.8 million in Q2 2022.
• A 5-year average of $13.5 million and a median of $13.3 million in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables tumbled 77.45% — and 2025, when it jumped 74.71%.
• Agios Pharmaceuticals' Accounts Payables stood at $18.6 million in 2022, then tumbled by 47.46% to $9.8 million in 2023, then jumped by 70.17% to $16.6 million in 2024, then grew by 10.29% to $18.4 million in 2025, then declined by 25.1% to $13.7 million in 2026.
• Business Quant data shows AGIO's Accounts Payables at $13.7 million in Q1 2026, $18.4 million in Q4 2025, and $19.6 million in Q3 2025.